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Abstract
Aims: To determine the clinical outcomes of an intensity-modulated radiotherapy technique for total mucosal irradiation (TM-IMRT) in patients with head and
neck carcinoma of unknown primary (HNCUP).
Materials and methods: A single-centre prospective phase II trial design was used in two sequential studies to evaluate TM-IMRT for HNCUP. Patients were
investigated for primary tumour site using examination under anaesthetic and biopsies, computed tomography  magnetic resonance imaging (MRI) or 18-
ﬂuorodeoxyglucose positron emission tomography-computed tomography (PET-CT). Patients received IMRT to the potential primary tumour sites and elec-
tive cervical nodes. Concomitant chemotherapy was used in patients who received primary radiotherapy or those with nodal extracapsular extension.
Results: Thirty-six patients with HNCUP were recruited; 72% male. Twenty-ﬁve patients (69.4%) had p16-positive disease. Two year mucosal and local nodal
control rates were 97.1% (95% conﬁdence interval 91.4e100) and 89.8% (78.4e100), respectively. One mucosal primary was detected 7.3 months after TM-IMRT
and three patients died from recurrent/metastatic squamous cell carcinoma of the head and neck. Twelve patients (33%) developed grade 3 (Late Effects in
Normal Tissue-Subjective, Objective, Management and Analytical; LENT-SOMA) dysphagia with a 1 year enteric tube feeding rate of 2.7%. The high-grade
subjective xerostomia rate (LENT-SOMA) at 24 months after IMRT was 15%.
Conclusions: At a median follow-up of 36.1 months, the use of TM-IMRT was associated with good local control. Toxicity was comparable with previously
reported TM-IMRT regimens encompassing similar mucosal volumes.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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The diagnosis of head and neck carcinoma of unknown
primary (HNCUP) comprises about 5% of all head and neck
cancers [1,2]. The most common histological subtype is
squamous cell carcinoma. Unlike carcinoma of unknown
primary presenting at sites below the clavicle, HNCUPAuthor for correspondence: C.M. Nutting, Royal Marsden NHS Foundation
Trust, Fulham Road, London SW3 6JJ, UK. Tel: þ44-207-808-2586; Fax:
þ44-207-808-2235.
E-mail address: Chris.Nutting@rmh.nhs.uk (C.M. Nutting).
http://dx.doi.org/10.1016/j.clon.2016.04.035
0936-6555/ 2016 The Royal College of Radiologists. Published by Elsevier Lt
creativecommons.org/licenses/by-nc-nd/4.0/).presenting with cervical lymph nodes has a much better
prognosis, with similar 5 year overall survival rates to head
and neck carcinomas with a known primary.
Due to the rarity of HNCUP, no randomised trials have
been completed. Following a detailed initial evaluation for
the potential primary tumour site, treatment typically in-
cludes modiﬁed radical neck dissection of involved lymph
nodes followed by adjuvant therapy with (chemo-) radio-
therapy. Some centres advocate neck dissection alone for
patients with N1 cervical lymph node disease and no
extracapsular extension (ECE). A valid alternative to neck
dissection is primary non-surgical treatment [3,4].d. This is an open access article under the CC BY-NC-ND license (http://
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of radiotherapy target volume and radiation dose to be
delivered to this volume [5]. Two markedly different ap-
proaches are commonly advocated: irradiation of the
postoperative hemi-neck only; or total mucosal and
comprehensive cervical node irradiation (TMI). The ﬁrst
approach has the advantages of low acute and long-term
morbidity, but the disadvantage of leaving any occult pri-
mary tumour site untreated. This can make subsequent
management very difﬁcult if the primary tumour manifests
itself after initial therapy. The second approach of TMI has
high acute and late morbidity rates due to irradiation of
many critical organs at risk, including the mucosa, major
and minor salivary glands, and the pharyngeal neuromus-
cular structures that are important for swallowing. A sys-
tematic review suggested that TMI reduced nodal relapse
and prevented the need for further surgery [6]. The dose
required to treat the potential site of unknown primary
tumour is also controversial, with opinions ranging from
elective to radical dose irradiation. In the design of this
study, we hypothesised that if the primary tumour site
remained undetected after a comprehensive investigation,
then the primary tumour could be considered microscopic
disease and that delivery of an elective dose would be
sufﬁcient.
The purpose of this study was to evaluate prospectively
the feasibility of an intensity-modulated radiotherapy
technique for total mucosal irradiation (TM-IMRT) to treat
thewhole upper aerodigestive tractmucosa and uninvolved
cervical neck nodes while, at the same time, reducing the
dose to salivary glands and the pharynx. In this way, we
wished to secure the beneﬁts of TMI without exposing pa-
tients to the long-term toxicities associated with conven-
tional TMI techniques.Materials and Methods
Patients and Trial Eligibility
This study was a pooled analysis of two single-centre,
phase II trials. Both studies were approved by the insti-
tutional research and ethics committee [Royal Marsden
Hospital CCR2823 and CCR3301 and NCT trials registra-
tion numbers NCT02112344 (CCR2823) and NCT02068313
(CCR3301)]. The aim of the ﬁrst study, CCR2823, was to
assess the safety and feasibility to deliver TM-IMRT. Once
that was completed, subsequent patients with HNCUP
were treated within a larger prospective phase II study
(CCR3301). The primary aim of CCR3301 was to deter-
mine a threshold radiation dose for the parotid glands
and allow radiobiological modelling of normal tissue
toxicity.
Patients with histologically conﬁrmed metastatic carci-
noma to the cervical lymph nodes (including N1 disease
with no ECE) with unknown primary tumour site, and
World Health Organization/Eastern Cooperative Oncology
Group performance status 0 or 1 were eligible. Exclusion
criteria were previous radiotherapy to the head and neck,previous malignancy excluding non-melanoma skin cancer,
previous or concurrent physical illness that in the in-
vestigator’s opinion would interfere with the completion of
therapy or follow-up. Prophylactic amifostine or pilocar-
pine was not allowed and use of brachytherapy was
prohibited.Evaluation
All patients underwent a full history and a physical ex-
amination by an experienced head and neck surgical
oncologist. Fibre optic nasendoscopic evaluation of the
upper aerodigestive tract was carried out as an outpatient
procedure. All patients were imaged by computed tomog-
raphy of the head, neck, chest and abdomen, supplemented
by whole body 18-ﬂuorodeoxyglucose positron emission
tomography-computed tomography (18F-FDG PET-CT) and/
or head and neck magnetic resonance imaging (MRI). 18F-
FDG PET-CT was not a routine investigation at our institu-
tion during the trial recruitment period. An examination
under anaesthesia was carried out in all cases, with biopsy
of any suspicious mucosal sites and unilateral or bilateral
tonsillectomy. All cases were discussed at the head and neck
oncology multidisciplinary team meeting. Patients were
staged using AJCC TNM 6th edition, 2002. Patients pro-
ceeded to neck dissection, as deemed appropriate for their
nodal stage. Patients provided fully informed consent.
Baseline blood tests included full blood count, urea, elec-
trolytes and liver function tests. No prophylactic feeding
tubes were inserted.Treatment
Intensity-modulated Radiotherapy for Total Mucosal
Irradiation
All patients in both studies were treated using the same
TM-IMRT protocol. They underwent a planning computed
tomography scan (2 mm slices) of the head and neck
immobilised in a customised shell. Target volumes and or-
gans at risk (parotid glands, spinal cord and brainstem)
were outlined according to published guidelines [7,8] and
radiotherapy planned using ﬁve- or seven-ﬁeld simulta-
neous integrated boost technique. Clinical target volume 1
(CTV1) was the ipsilateral level 1b to 5 cervical lymph node
levels (usually postoperative). CTV2 was the mucosa of the
nasopharynx, oropharynx, larynx and hypopharynx and the
contralateral level 2 to 5 cervical lymph nodes. For Cauca-
sian patients with EpsteineBarr virus-negative squamous
cell carcinoma and lymph node involvement conﬁned to the
lower cervical nodes (3 or 4), the nasopharynx was
excluded. A CTV to planning target volume (PTV) margin of
3 mmwas added to allow for patient and organ motion and
set-up errors. The radiation dose to the resulting PTV1 and
PTV2 was prescribed to the median of the PTV dose volume
histogram. The prescribed dose in 30 fractions was 60 Gy to
PTV1 and 54 Gy to PTV2. If macroscopic tumour was pre-
sent in the neck, 65 Gy was prescribed to PTV1.
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In the presence of lymph node ECE or when treatment
was single modality primary radiotherapy alone, concomi-
tant chemotherapy with two cycles of cisplatin 100 mg/m2
was given on days 1 and 29 of radiotherapy. Carboplatin
[area under the curve (AUC) ¼ 5] was substituted for
cisplatin if the glomerular ﬁltration rate was between 30
and 50 ml/min [9]. For inoperable patients, induction
chemotherapy was given with two cycles of cisplatin
(75 mg/m2) day 1 and 5-ﬂuorouracil (1000 mg/m2) days
1e4 on a 21 day cycle before TM-IMRT.
Toxicity and Tumour Assessments
Acute radiation toxicity was measured using National
Cancer Institute e Common Terminology Criteria for
Adverse Events (NCI-CTCAE v3.0). Patients were reviewed
weekly during treatment and for the ﬁrst month after
radiotherapy.
Late toxicity was measured using the Radiation Therapy
Oncology Group/European Organization for Research and
Treatment of Cancer and Late Effects in Normal Tissue-
Subjective, Objective, Management and Analytical (LENT-
SOMA) systems and was recorded at 3, 6, 12, 18 and 24
months after TM-IMRT.
Patients were assessed for locoregional tumour control
by clinical examination monthly in the ﬁrst year after
treatment, bimonthly in the second year and then at 3e6
monthly intervals up to 5 years. Computed tomography
scanning was carried out 2 months after the completion of
treatment and then as clinically indicated.
End Points and Statistical Analysis
The primary objective of this pooled analysis was to
evaluate the feasibility and safety of delivering TM-IMRT.
Secondary objectives were local control, progression-free
survival (PFS) and overall survival rates and to evaluate
acute and long-term toxicity, including xerostomia and
dysphagia.
In the initial phase II trial (CCR2823), feasibility was
deﬁned as >85% of 18 patients able to complete the full
course of radiotherapy, with no treatment breaks or
extension to the planned treatment time resulting from
treatment-related acute toxicity. Two patients were simul-
taneously recruited and enrolled from separate clinics to
the ﬁnal study place. Therefore 19 patients were included.
Data from a further 17 patients with HNCUP were collected
from a second phase II trial (CCR3301) within a larger
cohort of head and neck cancer patients.
The incidence of acute or late toxicity was deﬁned as the
total number of patients reaching that grade at any time
divided by the total number of assessable patients [10].
Clinical end points for this pooled analysis: all patient
overall survival, PFS, local control and locoregional control
(LRC) were calculated from the start date of radiotherapy
using KaplaneMeier methods. A post-hoc subgroup anal-
ysis of overall survival according to previously reported risk
groupings (p16 status, N-stage and tobacco use) [11] wascalculated from the start date of radiotherapy using
KaplaneMeier methods. The cut-off date for statistical
analysis was 1 May 2014.Results
Patient Characteristics and Treatment Compliance
Between July 2007 and December 2012, 36 patients were
entered into the two trials. Twenty-six patients were male
(72%) and the median age (range) at diagnosis was 54.2
(43e86.9) years. The histological subtype was squamous
cell carcinoma in 35 patients (97%) and one patient had
undifferentiated carcinoma of nasopharyngeal type. Cervi-
cal nodal disease was unilateral in 33 patients (92%) and
most frequently affected cervical lymph node levels 2 and/
or 3 (88%). A history of heavy tobacco smoking (>10 pack
years) was seen in 18 patients (50%) and a prevalence of p16
positivity, a surrogate for human papillomavirus (HPV)
infection, was 25 of 36 patients (69%). All patients under-
went computed tomography of the head, neck, chest and
abdomen. PET-CT was carried out in 16 patients (44.4%) and
MRI in 26 (72.2%) patients. Neck dissections were selective
in 13.9%, modiﬁed radical in 66.7%, radical in 5.6% and
extended radical in 5.6%. Radiotherapy started at a median
(interquartile range) of 42 (36e45) days after neck dissec-
tion. All patients received the planned course of TM-IMRT in
the scheduled time with a median (interquartile range)
treatment duration of 41 (39e41) days. Six patients were
treated with 65 Gy to PTV1 (in three patients this was pri-
mary radiotherapy for inoperable lymphadenopathy and in
three patients because of a positive neck dissectionmargin).
Concomitant chemotherapy was administered to 18 pa-
tients, 15 (42%) patients for ECE and three (8%) patients with
primary radiotherapy, one (3%) patient received induction
chemotherapy. Patient and treatment characteristics are
presented in Tables 1 and 2.
Acute Toxicity
The acute locoregional toxicities are reported in
Supplementary Table S1. The incidence of grade 3 dysphagia
and mucositis were 33% and 42%, respectively. Of the pa-
tients with grade 3 dysphagia, 10 required feeding via
nasogastric tube and two via radiologically inserted gas-
trostomy tube. The median (range) feeding tube dwell time
was 35 (22e804) days, with all patients tube-free at last
follow-up. One patient (2.7%) developed grade 4 fatigue at
week 1 after completion of TM-IMRT. This recovered to
grade 1 by week 8 after treatment. The mean (range) radi-
ation doses to the ipsilateral and contralateral parotid
glands were 36.3 (27.3e48.7) Gy and 29.9 (20.1e36.0) Gy,
respectively. Twenty-three patients (64%) developed
acute  grade 2 xerostomia. All other acute toxicities were
predominantly grade 1 or 2. One patient (61 year old, fe-
male, p16-negative, never smoker) who received adjuvant
TM-IMRT with no induction or concomitant chemotherapy
became acutely unwell 16 days after radiotherapy was
Table 1
Patient and tumour characteristics
Characteristic
Number of patients 36 (100)
Follow-up (months)
Median (range) 36.1 (0.5e76.6)
Age (year), median (range) 54.2 (43.5e86.9)
Gender
Male 26 (72)
Female 10 (28)
Performance status
0 25 (69)
1 11 (31)
Tobacco exposure
Never smoker 15 (42)
Former smoker 17 (47)
Current smoker 4 (11)
Tobacco-smoking history
10 pack-years 18 (50)
>10 pack-years 18 (50)
P16 expression
Positive 25 (69)
Negative 9 (25)
Unknown 2 (6)
Nodal stage
N1 3 (8)
N2a 9 (25)
N2b 19 (53)
N2c 3 (8)
N3 2 (6)
Histology
Squamous cell carcinoma 35 (97)
UCNT 1 (5)
Levels of nodal involvement
Level 1b 2 (4)
Level 2 33 (58)
Level 3 17 (30)
Level 4 4 (7)
Level 5 1 (2)
Total 57 (100)
UCNT, undifferentiated carcinoma of nasopharyngeal type.
Values are number (percentage) unless otherwise noted.
Table 2
Treatment characteristics
Characteristic
Induction chemotherapy
Cisplatin/5-ﬂuorouracil (two cycles) 1 (3)
None 35 (97)
Concomitant chemotherapy
Cisplatin day 1, day 29 11 (31)
Carboplatin day 1, day 29 4 (11)
Cisplatin day 1, carboplatin day 29 3 (8)
None 18 (50)
Radiation (IMRT)
Primary radical 3 (8)
Adjuvant (postoperative) 33 (92)
Involved nodal dose (PTV1)
65 Gy 6 (17)
60 Gy 30 (83)
Mucosal tube dose (PTV2)
54 Gy 36 (100)
Parotid doses (Gy)
Ipsilateral, mean (range) 36.3 (27.3e48.7)
Contralateral, mean (range) 29.9 (20.1e36)
IMRT, intensity-modulated radiotherapy; PTV, planning target
volume.
Values are number (percentage) unless otherwise noted.
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acute cardiac failure. No other deaths were reported within
90 days of completing treatment.Late Toxicity
Supplementary Tables S2AeE (3, 6,12,18 and 24months)
list the TM-IMRT-related late adverse events (LENT-SOMA).
The most frequent late toxicity was xerostomia, with 
grade 2 subjective xerostomia reported in 27%, 17% and 15%
of patients at 6, 12 and 24 months, respectively (Figure 1a).
One patient (3%) remained feeding tube dependent at 12
months and subsequently underwent a videoﬂuoroscopy at
15 months after TM-IMRT (Figure 1b), where a benign ste-
nosis was noted at the cricopharyngeus. Pharyngoscopy and
balloon dilatation were carried out on three occasions at 16,
17 and 24 months after TM-IMRT. The radiologicallyinserted gastrostomy tube was removed at 29 months and
the patient currently has no residual dysphagia 38 months
after TM-IMRT. No other grade 3 or higher toxicities were
noted at 12 months after TM-IMRT.Outcomes
Primary Mucosal, Nodal and Distant Control and Overall
Survival
At a median follow-up of 36.1 months for all patients
(45.5 months for surviving patients), the median time for
all survival and recurrence outcomes has not been reached
(Figure 2aed, Table 3). The LRC rate at 2 years was 89.8%
(95% conﬁdence interval 78.4e100). The primary mucosal
control rate at 2 years was 97.1% (95% conﬁdence interval
91.4e100) and the nodal control rate was 89.8% (95%
conﬁdence interval 78.4e100). At data cut-off, six patients
(16.7%) had died. Three of these deaths were from causes
unrelated to HNCUP. One, with >100 pack-year smoking
history, developed a second primary non-small cell lung
cancer and died 15 months after treatment. A second pa-
tient died from alcoholic liver disease 21.5 months after
treatment. Neither had evidence of HNCUP recurrence. A
third patient died of acute congestive cardiac failure,
which occurred 16 days after the completion of post-
operative radiotherapy and was considered unrelated to
treatment.
One patient suffered tumour recurrence in the base of
tongue 7.3 months after radiotherapy. This patient initially
presented with stage T0N2bM0 disease and was p16 posi-
tive. Computed tomography and MRI staging did not reveal
a primary. However, PET-CT was not carried out. At the time
of recurrence, radiological staging revealed synchronous
Fig 1. (A) Incidence of subjective xerostomia (Late Effects in Normal
Tissue-Subjective, Objective, Management and Analytical; LENT-
SOMA) over time, low grade (0e1) versus high grade (2e4).
(B) Incidence of subjective pharyngo-oesophageal dysphagia (LENT-
SOMA) over time, low grade (0e2) versus high grade (3e4).
T.M. Richards et al. / Clinical Oncology 28 (2016) e77ee84 e81metastatic contralateral level 2 and 3 cervical lymph nodes.
Both mucosal and lymph node recurrences were within
PTV2 and had received 54 Gy in 30 fractions. The recurrence
was too extensive for curative resection and the patient
received two lines of palliative chemotherapy, but pro-
gressed and died 16.4 months after TM-IMRT.
Two other patients developed local nodal recurrences,
both were within PTV1, which had received 65 Gy in 30
fractions. The ﬁrst patient had stage N2c disease and
received primary radical chemo-IMRT, but recurred 22.5
months after treatment. He underwent salvage neck
dissection and remains disease free 55 months after treat-
ment. The second patient initially presented with unilateral
N3 nodal disease with ECE. He received adjuvant chemo-
IMRT, but developed cervical nodal and distant metastatic
disease 3.7 months after treatment. He received palliative
radiotherapy, but died 2 months later.
A post-hoc subgroup analysis of overall survival, ac-
cording to the three previously reported risk stratiﬁcationgroups (low, intermediate and high) [11] showed that 2 year
overall survival rates (95% conﬁdence interval) for low-
(n¼ 19), intermediate- (n¼ 8) and high-risk (n¼ 7) patients
were 100% (n.d), 70% (50.6e89.6) and 42.9% (21.3e64.5),
respectively. Two patients (5.5%) were excluded from this
analysis as p16 status was not assessable. No statistically
signiﬁcant difference was seen between risks groups
(P > 0.05), but numbers were small.Discussion
In this pooled analysis of two prospective phase II
studies, we found that delivery of TM-IMRT for HNCUP was
feasible and well tolerated with moderate rates of acute and
late radiotherapy-related adverse events.
Nine retrospective studies (Table 4) have reported their
toxicity and efﬁcacy outcomes using IMRT for HNCUP. All
gave partial or TMI treating the mucosa to various radiation
doses. Unlike this study, the radiotherapy technique and
target volumes were heterogeneous and only four studies
[14,15,18,19] collected prospective toxicity data. However,
despite the drawbacks of a retrospective study design, these
currently provide the best data on outcomes for IMRT in
HNCUP.
Treating the involved nodes or high-risk, postoperative
resection bed with a high radiation dose is standard for
HNCUP in most series. The 2 year LRC rate in our study
(89.8%) was similar to previous reports where LRC > 80%
were reported in all IMRT studies (Table 4). Also similar to
other studies, no local or distant recurrence occurred later
than 2 years after IMRT. The development of a mucosal
primary is uncommon after radiotherapy with either IMRT
or non-IMRT techniques [6]. Rates of primary mucosal
control remain above 90% in all IMRT series (Table 3),
including our data, 97.1% at 2 years.
Our study conﬁrms comparable salivary gland toxicity
with rates of high-grade xerostomia of 17% and 15% at 12
and 24 months, respectively. In other trials of IMRT for
HNCUP, rates of high-grade subjective xerostomia were
5e36% at 6 months and 0e8% at 24 months after IMRT
[14,18].
In our study, we report an oesophageal stricture rate of
5%, which compares favourably with the 2e54% reported by
others and our 1 year feeding tube rate was 5%, similar to
the 0e5% reported by others. Studies with a higher oeso-
phageal stenosis rate had a greater use of chemo-IMRT and
a higher median radiation dose to the mucosal tube and
pharyngeal muscles. The best reported local and distant
control rates by Sher et al. [12], with no local or distant
recurrence, were probably due to a higher radiotherapy
dose (60 Gy to mucosal tube) and a 92% use of concomitant
chemotherapy. This came at the cost of signiﬁcantly
increased acute and late toxicity.
Data for the survival beneﬁt of using concomitant
platinum chemotherapy in the treatment of HNCUP have
been extrapolated from the 6.5% overall survival
improvement seen in squamous cell carcinoma of the head
and neck with a known primary site (HNCUP patients
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Fig 2. (A) Overall survival rate for patients treated with total mucosal
and bilateral neck irradiation. (B) Progression-free survival rate for
patients treated with total mucosal and bilateral neck irradiation. (C)
Local mucosal (T) control rate for patients treated with total mucosal
T.M. Richards et al. / Clinical Oncology 28 (2016) e77ee84e82excluded) [21]. Our data suggest that the acute and late
oesophageal and pharyngeal toxicity with the addition of
platinum chemotherapy is worsened. Seven of the eight
patients who developed acute grade 3 pharyngeal or
oesophageal dysphagia, and the single patient who
developed an oesophageal stenosis, all received concomi-
tant chemotherapy. The additional toxicity from chemo-
therapy has previously been noted by Chen et al. [22], who
reported the outcomes of 60 patients treated for HNCUP at
a single institution. Thirty-two patients (53%) received
concurrent cisplatin chemotherapy and the oesophageal
stricture rate was signiﬁcantly higher, being 34% in the
chemoradiotherapy group compared with 7% in the
radiotherapy alone group. The enteric feeding tube rate
was also signiﬁcantly higher at 6 and 12 months, 28%
versus 4% and 16% versus 0%, respectively, when
comparing chemoradiotherapy with radiotherapy alone
groups. No additional beneﬁt for overall survival or LRC
with the addition of chemotherapy was shown. In our
study we reserved concomitant chemotherapy only for
patients with high-risk features, e.g. cervical lymph node
ECE or with primary radiotherapy.
The signiﬁcance of HPV status in oropharyngeal carci-
nomawas reported by Ang et al. [11], who showed that HPV
status was a strong and independent prognostic factor
alongside tobacco smoking, primary tumour and nodal
stage, for overall survival. There are limited data on the
incidence of HPV in patients with HNCUP. Two recent
studies [12,23] have assessed this. Sher et al. [12] tested HPV
status in 15 of 24 patients with a prevalence in tested pa-
tients of 47%. Smoking history was not reported for the
HPV-tested group and neither were survival outcomes
related to HPV status. Tribius et al. [23] tested cervical
lymph node samples from 63 patients treated at two
German centres with radiotherapy for HNCUP
(2002e2011). They were retrospectively analysed for
HPV16/33 and p16 status. The p16 and HPV16/33 positivity
rates were 57% and 52%, respectively. Current/former
smokers comprised 79%, with 88% of these reporting a >10
pack-year smoking history. No signiﬁcant 2 year overall
survival or PFS difference was seen between HPV16/33þ/p-
16þ and other groups. The results were reported as being
consistent with the data of Ang et al. [11], indicating that a
heavy smoking history seems to counteract the positive
prognostic effect of tumour HPV positivity. In our study, the
p16 positivity rate of 69% was similar to Tribius et al. [23].
Smoking was less prevalent, but those who did smoke had a
higher tobacco exposure (60% current/former smokers and
97% > 10 pack-year smoking history). Our 2 year overall
survival and PFS outcomes compared with Tribius et al. [23]
were also similar at 81.3% and 77.6% (current study) versus
75% and 70%, respectively. Our analysis of tumour controland bilateral neck irradiation. (D) Locoregional progression-free sur-
vival rate for patients treated with total mucosal and bilateral neck
irradiation. Vertical bars indicate the 95% conﬁdence interval for the 2
year survival rate.
Table 3
Treatment outcomes at 2 years
Survival 2 year survival rate
(95% conﬁdence interval)
Overall survival 81.3% (67.6e95.0)
PFS 77.6% (62.5e92.7)
Locoregional (lymph node
and mucosa) PFS
89.8% (78.4e100)
Primary mucosal PFS 97.1% (91.4e100)
Cervical lymph node PFS 89.8% (78.4e100)
PFS, progression-free survival.
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T.M. Richards et al. / Clinical Oncology 28 (2016) e77ee84 e83and survival for the three prognostic groups proposed by
Ang et al. showed better outcomes for HPV-positive cases,
but this did not reach statistical signiﬁcance. Presently,
there is no clear indication that radiation target volumes or
doses can be varied depending on HPV status. It is hoped
that further studies speciﬁcally with the exclusion of the
hypopharynx and larynx in p16þ cases, as reported in
retrospective studies [16,24], will clarify this matter. This
has the potential for signiﬁcant amelioration of radiation-
induced toxicities.
Finally, the risk of radiation-induced secondmalignancy
must be considered carefully when treating large elective
treatment volumes in patients with a good long-term
prognosis. No data are yet reported on the second malig-
nancy rate for patients treated with IMRT to the head and
neck. The rate in large population-based studies with
heterogeneous primary tumour sites is low at 0.5e1% at
>10 years after radiotherapy [25e27]. However, it is a
potentially life-threatening consequence for a small mi-
nority of patients. A meta-analysis of non-IMRT-treated
patients showed a linear dose-response relationship be-
tween increasing radiation dose to normal tissue and
second malignancy rate for most organs [28]. Therefore, a
reduction in radiation dose to the putative primary
mucosal sites at risk may decrease the rate of second
malignancy.
The limitations of this study are the small number of
patients and only 44% underwent staging PET-CT, as this
was not standard at our institution during the recruitment
period. Head and neck MRI was carried out for all patients
who did not undergo PET-CT. There were several beneﬁts:
it is the largest prospective study to date of HNCUP treat-
ment; all patients received a consistent radiotherapy
technique and dose; and detailed prospective acute and
late toxicity data were collected.
To our knowledge, this is the largest prospective
study of TM-IMRT for the treatment HNCUP. IMRT
delivering a high dose (60e65 Gy) to the involved nodal
region and a prophylactic dose (54 Gy) to the entire
mucosal tube (nasopharynx, oropharynx, larynx and
hypopharynx) is feasible and tolerable. Rates of LRC and
mucosal failure are comparable with previously re-
ported IMRT studies. Prospective accrual of HNCUP pa-
tients treated with this IMRT protocol continues within
the Royal Marsden Hospital phase II expansion trial
(NCT02068313).
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